Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populations

Hillary Cuesta | Ibrahim El Menyawi | Alphonse Hubsch
Liane Hoefferer | Orell Mielke | Susie Gabriel | Amgad Shebl

1CSL Behring, King of Prussia, Pennsylvania, USA
2CSL Behring AG, Bern, Switzerland
3CSL Behring Innovation GmbH, Marburg, Germany
4CSL Limited, Parkville, Melbourne, Australia

Correspondence
Alphonse Hubsch, CSL Behring AG, Bern, Switzerland.
Email: alphonse.hubsch@cslbehring.com

Funding information
CSL Behring

Abstract

Background: Severe hemolysis rarely occurs in patients receiving intravenous immunoglobulin (IVIG) therapy. A systematic review was performed to assess the incidence of IVIG-related hemolysis and the impact of patient and product risk factors.

Study Design and Methods: A systematic literature search for terms related to “IVIG products”, “hemolysis,” and “adverse events” was conducted in Embase for articles published between January 1, 2015, and May 31, 2021. Studies with no clinical datasets, no IVIG treatment, or where IVIG was used to treat hemolytic conditions were excluded. Of the 430 articles retrieved, 383 were excluded based on titles/abstracts and 14 were excluded after in-depth review.

Results: In total, 33 articles were analyzed and separated into observational studies (n = 16), clinical trials (n = 8), and case reports (n = 9). The incidence proportion for IVIG-related hemolysis ranged from 0% to 19% in observational studies and 0%–21% in clinical trials. A higher incidence of IVIG-related hemolysis was consistently reported in patients with blood groups A and AB. Hemolysis occurred more frequently in patients treated with IVIG for some conditions such as Kawasaki disease; however, this may be confounded by the high dose of IVIG therapy. IVIG-related hemolysis incidence was lower in studies using IVIG products citing manufacturing processes to reduce isoagglutinin levels than products that did not.

Conclusion: This analysis identified patient and product risk factors including blood group, IVIG dose, and IVIG manufacturing processes associated with elevated IVIG-related hemolysis incidence.

Abbreviations: CBC, complete blood count; CIDP, chronic inflammatory demyelinating polyneuropathy; EtOH, ethanol; GBS, Guillain-Barré syndrome; Hb, hemoglobin; IAC, immunoaffinity chromatography; Ig, immunoglobulin; ITP, immune thrombocytopenia; IVIG, intravenous immunoglobulin; KD, Kawasaki disease; MG, myasthenia gravis; MMN, multifocal motor neuropathy; MS, multiple sclerosis; N.R., not reported; OA, ethanol-octanoic acid; PEG, polyethylene glycol; PI, primary immunodeficiency; SID, secondary immunodeficiency.
1 | INTRODUCTION

Intravenous immunoglobulin (IVIG) products consist of immunoglobulin (Ig) G purified from the plasma of healthy donors. Initially, IVIG products were used as replacement therapy in patients with immunodeficiency syndromes but are now also used as immunomodulatory treatment in autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenia (ITP), Guillain-Barré syndrome (GBS), and Kawasaki disease (KD). Although rare, the use of Ig is sometimes associated with hemolysis, with studies suggesting that isoagglutinins in products are a probable cause. Plasma for IVIG production is obtained from donors of all ABO blood groups, the majority being groups O and A; therefore, plasma for IVIG contains IgG anti-A and anti-B antibodies, as postulated by Landsteiner’s Law. Common consequences of hemolysis include anemia and jaundice. However, if not appropriately managed, hemolysis can lead to more severe complications, such as renal failure, shock with multiorgan failure, and even death.

The aim of this review is to assess the incidence of IVIG-related hemolysis and the impact of patient and product risk factors by means of a systematic review of published literature.

2 | METHODS

We performed a systematic literature search in Embase using a search algorithm to identify articles on IVIG-related hemolysis. The search algorithm contained terms related to IVIG products, including product brand names, hemolysis, and adverse events (full search string provided in Appendix S1). We searched for articles published between January 1, 2015, and May 31, 2021. Titles and abstracts from the search results were screened independently by two authors to identify any articles describing hemolysis in patients receiving IVIG, which were selected for subsequent in-depth review. Studies with no IVIG treatment, articles on unrelated topics, studies reporting IVIG used to treat hemolytic conditions (autoimmune hemolytic anemia, hemolytic disease of the newborn, etc.), review articles, clinical guidelines, and other articles that did not present clinical data or case counts were excluded. Relevant full-text articles were screened in-depth to extract information such as the definition of hemolysis used, the incidence of hemolysis in the population, indication, IVIG dose, and blood group. At this stage, any duplicates, congress abstracts, and studies among hemolysis cases only (thus lacking a denominator to calculate the incidence of hemolysis) were excluded. We included both observational real-world studies, and clinical trials in our review, however, due to differences in methodology and follow-up between these two types of studies, we report these incidence proportions separately. Two reviewers screened titles/abstracts independently, rated each independently, and met to resolve any discrepancies in ratings. This process was then repeated for full-text article review. The review was not registered, and a protocol was not prepared.

3 | RESULTS

Following the screening of titles and abstracts, 430 total search results were selected for detailed data extraction.
| Reference          | Study type                  | Number of patients receiving IVIG | IVIG product and manufacturing process (where reported) | Primary patient population and indication(s)/IVIG dose | Blood group details of the study population | Number of hemolysis cases | IVIG dose of patients with hemolysis | Hemolysis incidence estimate | Blood group details of patients with hemolysis |
|-------------------|-----------------------------|----------------------------------|--------------------------------------------------------|------------------------------------------------------|-------------------------------------------|-------------------------|-------------------------------|---------------------------------|----------------------------------|
| Keh et al. 2020   | Retrospective cohort        | 90                               | N.R.                                                   | Adult patients with CIDP or MMN/Mean dose: 1.57 g/kg/month | N.R.                                      | 0                       | N.R.; no hemolysis observed in IVIG-treated patients | Clinically significant hemolysis: 0% (0–3.3) per patient; 0% (0–0.16) per infusion | N.R.                             |
| Nolan et al. 2018 | Retrospective cohort        | 419 (123 with CBC data to evaluate hemolysis) | N.R.                                                   | Pediatric patients with KD/Dose: 2 or 4 g/kg | N.R.                                      | 18                      | 2/18 (11%): 2 g/kg 16/18 (89%): 4 g/kg | 15%; risk factors were Non-African-American race, higher IVIG dose and higher pre-IVIG Hb | A: 8/18 (44%) B: 5/18 (28%) AB: 4/18 (22%) O: 1/18 (6%) |
| Cicha et al. 2018 | Retrospective cohort        | 16                               | N.R.                                                   | Adult patients with dermatological conditions/Dose: 1–3 g/kg | A: 4/16 (25%) B: 4/16 (25%) AB: 1/16 (6%) O: 3/16 (19%) N.R.: 4/16 (25%) | 1                       | 2 g/kg                                      | 6.25%                           | A+: 1/1 (100%)                  |
| Sridhar et al. 2018 | Retrospective cohort        | 20,440                           | Multiple manufacturing methods                        | N.R. (multiple indications)/Dose: N.R.               | N.R.                                      | 211                     | N.R.                                        | Hemolysis occurring same day: 1% | N.R.                             |
| Liu et al. 2018   | Retrospective cohort        | 55                               | N.R.                                                   | Adult and pediatric patients with small-fiber polyneuropathy/ Dose: ≥1 g/kg/4 weeks | N.R.                                      | 1                       | N.R.                                        | 1.8%                            | N.R.                             |
| Donga et al. 2017 | Database (claims/EMR study) | 1061                             | N.R.                                                   | Adult patients with ITP/Dose: N.R.                   | N.R.                                      | 12 cases of HA (used as proxy for intravascular hemolysis) | N.R.                           | Hemolytic anemia occurring within 3 days: 1.1% | N.R.                             |
| Akman et al. 2017 | Prospective cohort          | 31                               | N.R.                                                   | Multiple indications/ Dose: 2 g/kg                  | A: 14/31 (45%) B: 3/31 (10%) AB: 1/31 (3%) O: 13/31 (42%) | 6                       | N.R.                                        | Hemolysis occurring within 3–10 days: 19% | A+: 4 (66.6%) AB+: 1 (16.7%) O+: 1 (16.7%) |
| Reference         | Study type          | Number of patients receiving IVIG | IVIG product and manufacturing process (where reported) | Primary patient population and indication(s)/IVIG dose | Blood group details of the study population | Hemolysis case information                                                                 |
|-------------------|---------------------|----------------------------------|--------------------------------------------------------|-------------------------------------------------------|---------------------------------------------|------------------------------------------------------------------------------------------------|
| Levine et al. 2017 | Retrospective cohort | 166                              | Multiple manufacturing methods                         | Patients with CIDP, MMN, polymyositis, dermatomyositis, MG and MS/Mean dose: 1.2/kg/month | N.R.                                        | 0; no patients with clinically significant hemolysis                                      |
| Winiecki et al. 2015 | Database (FAERS)   | 236 suspected hemolysis          | N.R.                                                   | Patients with CIDP, GBS, ITP, KD, MG and PI/Dose: 0.8–4 g/kg | N.R.                                        | 109 Dosing information available for 80 patients: 8.3% (66/800) had ≥2 g/kg               |
| Quinti et al. 2015 | Prospective cohort | 162 (142 regularly received IVIG in hospital at intervals of 2/3 weeks; 20 patients self-administered SCIG) | N.R.                                                   | Patients with primary antibody deficiency/Mean dose: 0.3 g/kg/month | N.R.                                        | 6 Monthly dose of 0.37–0.46 g/kg                                                         |
| Ghiasi et al. 2017 | Retrospective cohort | 67                               | N.R.                                                   | Adult and pediatric patients with dermatologic conditions/Mean dose: 2.01 ± 1.38 g/kg | N.R.                                        | 1 N.R. 1.5%                                                                             |
| Reference | Study type | Study information | IVIG product and manufacturing process (where reported) | Primary patient population and indication(s)/IVIG dose | Blood group details of the study population | Hemolysis case information | Blood group details of patients with hemolysis |
|-----------|------------|-------------------|--------------------------------------------------------|---------------------------------|-----------------------------------------------|-----------------------------|-----------------------------------------------|
| **Wallenhorst et al. 2020**<sup>7</sup> | Database (claims/EMR study) | Study period 1: 9439 | Ethanol octanoic acid | Adult and pediatric patients with any indication, including PI, SID, GBS, KD, CIDP, MG and ITP; Mean dose: 0.76 (Period 1) to 0.85 (Period 2) g/kg | N.R. | 38 | N.R. | N.R. |
| | | Study period 2: 7710 | Ethanol octanoic acid donor screening | | | 20 | <1 g/kg: 9; 1–1.5: 0; >1.5: 10; Unknown: 1 |
| | | Study period 3: 7759 | Ethanol octanoic acid with IAC | | | 3 | <1 g/kg: 1; 1–1.5: 0; >1.5: 2 |
| **Van Anh et al. 2020**<sup>8</sup> | Cohort study | 562 | Ethanol fractionation followed by ion exchange chromatography | Patients with acute KD/Dose: 2 g/kg (additional dose if refractory) | N.R. | 4 (2 IVIG-responsive; 2 IVIG-resistant) | 2/4 (50%): 2 g/kg 2/4 (50%): 4 g/kg | 0.71% |
| **Bruggeman et al. 2020**<sup>9</sup> | Retrospective cohort | 581 (cohort 1: 440; cohort 2: 141) | Various brands | Pediatric patients with KD/Dose: 2 g/kg (max 70 g) | N.R. | Cohort 1: 20  Cohort 2: 13 | N.R., but IVIG dose was a risk factor  Cohort 1: 4.5%  Cohort 2: 9.2% | A: 1 (25%)  A+: 1 (25%)  Unknown: 2 (50%) |
| **Tong et al. 2020**<sup>10</sup> | Prospective cohort | 42 patients (50 samples) | Various brands | Patients with autoimmune disorders/Dose: ≥2 g/kg | N.R. | 20 | 40% | A: 8/20 (40%)  B: 5/20 (25%)  AB: 7/20 (35%) |
| **Pendergrast et al. 2021**<sup>11</sup> | Prospective observational study | 78 patients; 99 infusions | Multiple manufacturing methods | Adult and pediatric patients with neurologic Conditions: CIDP, GBS, MG or MMN (63%), ITP (13%), other conditions: dermatologic, rheumatologic and miscellaneous conditions (24%) Dose: ≥2 g/kg | Non-blood group O patients: A: 43/78 (55%); B: 25/78 (32%); AB: 9/78 (12%); Other: 1/78 (1%) | 31 | Average dose: 2.0 ± 0.1 g/kg | 40% | A: 14/31 (45%)  B: 9/31 (29%)  AB: 8/31 (26%) |
| Reference            | Study type       | Number of patients receiving IVIG | IVIG product and manufacturing process (where reported) | Primary patient population and indication(s)/ IVIG dose | Blood group details of the study population | Hemolysis case information | Hemolysis incidence estimate | Blood group details of patients with hemolysis |
|----------------------|------------------|-----------------------------------|--------------------------------------------------------|--------------------------------------------------------|---------------------------------------------|-----------------------------|-------------------------------|-----------------------------------------------|
| Leger et al. 2019¹²   | Interventional   | 22                                | Ethanol octanoic acid with IAC                         | Adult patients with MMN/Dose: 1–2 g/kg every 4–8 weeks | N.R.                                        | 0                           | N.R.; no hemolysis observed in IVIG-treated patients | N.R.                            |
| Koochakzadeh et al. 2018¹³ | Interventional   | 49                                | N.R.                                                   | Pediatric patients with acute ITP/Dose: 1 g/kg         | N.R.                                        | 0                           | N.R.; no hemolysis observed in IVIG-treated patients | N.R.                            |
| Mielke et al. 2017²⁴  | Single-arm trial | 57                                | Ethanol octanoic acid                                  | Adult patients with ITP/Dose: 1–2 g/kg                 | A: 30/57 (53%) B: 11/57 (19%) O:16/57 (28%) | 12                          | Mild hemolysis evaluated at day 9: 21.1% | A: 10/12 (8.3%) B: 2/12 (17%) |
| Viallard et al. 2017²⁵ | Single-arm trial | 22                                | Cohn fractionation                                     | Adult patients with PI/Dose: 0.2–0.8 g/kg every 3–4 weeks | N.R.                                        | 0                           | N.R.; no hemolysis observed in IVIG-treated patients | N.R. (0 cases in 9 months) |
| Lakkaraja et al. 2016²⁶ | Interventional   | 102; Arm A n = 51, Arm B n = 51   | N.R.                                                   | Pregnant women with fetal and neonatal alloimmune thrombocytopenia/ Dose: 2 g/kg (Arm A) or 1 g/kg (Arm B) | A: 40% B: 11% AB: 4% O: 4.5% | 30 (Arm A, n = 21; Arm B n = 9) | Arm A: 21/36 (58%) Arm B: 9/33 (27%) | N.R.                             |
| Melamed et al. 2016²⁷  | Single-arm trial | 25                                | Ethanol fractionation followed by ion exchange chromatography | Pediatric patients with PI/Dose: 0.3–0.8 g/kg per infusion | N.R.                                        | 0                           | N.R.; no hemolysis observed in IVIG-treated patients | Hemolysis occurring within 3 days of infusion: 0% |
| Karelis et al. 2019²⁸  | Single-arm trial | 49                                | Ethanol octanoic acid followed by chromatography       | MG exacerbations/ Dose: 2 g/kg                          | N.R.                                        | 5                           | N.R.                          | 10.2%                           |

(Continues)
Out of the 430 articles, 383 records were excluded based on the title and abstract and a further 14 articles were excluded based on the defined exclusion criteria (Figure 1). This left a total of 33 relevant articles, of which 16 were observational real-world studies, eight were clinical trials (both summarized in Table 1; with hemolysis definitions/assessments described in Table S1), and an additional nine were case reports (summarized in Table 2).

4 | PATIENT CHARACTERISTICS

4.1 | Observational real-world studies

Among the 16 observational, real-world studies included in this review, the patient sample size ranged from 16 to over 20,000 patients (Table 1). Patients treated with IVIG were aged between 2 and 85 years old and 52% were male (sex breakdown detailed in 12 studies \(^6-12,14-17,21\)).

The most commonly reported conditions treated by IVIG included KD (three studies \(^7,18,19\)) and dermatologic conditions (two studies \(^8,16\)). Other conditions included CIDP or multifocal motor neuropathy (MMN), immune thrombocytopenia (ITP), and small-fiber polyneuropathy. \(^6,10,11\) In total, eight studies included patients with multiple diseases treated with IVIG. \(^9,12-15,17,20,21\) Of the 16 studies, five reported the blood group details from the whole study population. The most common blood group was group A (range 25%–64%) and group O (range 19%–42%), followed by group B and AB (ranges 10%–32% and 3%–14%, respectively). \(^6,12,15,20,21\) Two studies included only patients with non-O blood group. \(^20,21\) Where patient populations were stated, there was a total of 514 reported hemolysis cases observed across real-world studies from a combined population of 49,836 patients (Table 1).

4.2 | Clinical trials

From the eight clinical trials included, patient sample size ranged from 22 to 102 patients (Table 1). Patients treated with IVIG were between 3 and 82 years old and 64% were male (sex breakdown detailed in seven of the eight clinical trials \(^22-25,27-29\)). Reported conditions being treated by IVIG in these clinical trials included ITP (three studies \(^23,24,26\)), with other studies including patients with CIDP, \(^29\) MMN, \(^22\) or myasthenia gravis (MG). \(^28\) Two studies included patients with primary immunodeficiencies treated with IVIG. \(^25,27\) From all studies combined there was a total of 47 reported hemolysis cases among 419 patients treated with IVIG included in the trials.
| Reference                  | Patient details                  | IVIG dose                              | First dose of IVIG | Indication | Blood group | Drop in Hb                                      |
|----------------------------|----------------------------------|----------------------------------------|--------------------|------------|-------------|------------------------------------------------|
| Shimomura et al. 2020      | 3-year-old Asian male            | 2 g/kg followed by an additional 2 g/kg 4 days later | Yes                | KD         | A+          | Nadir: 57 g/L; Baseline: 110 g/L; Drop: 53 g/L |
| Chadha et al. 2019         | Case 1: 75-year-old male Case 2: 59-year-old female Case 3: 20-year-old female | N.R.                                    | N.R.               | Patient 1: MG Patient 2: MG Patient 3: GBS | Case 1: AB+ Case 2: AB+ Case 3: A+ | Case 1: Drop: 3 g/dL Case 2: Drop: 5 g/dL Case 3: Drop: 6 g/dL |
| Lasica and Zantomio 2016   | 63-year-old male                 | 1.4 g/kg over 3 days                   | N.R.               | CIDP       | O           | Nadir: 120 g/L; Baseline: 140 g/L; Drop: 20 g/L |
| Sharma and Aryal 2018      | 56-year-old Asian male           | 2 mg/kg over 5 days                    | Yes                | GBS        | A+          | Nadir: 8.3 g/dL; Baseline: 15.3 g/dL; Drop: 7 g/dL |
| Tocan et al. 2017          | 10-month-old male                | 2 g/kg                                 | Yes                | KD         | A-          | Nadir: 3.4 g/dL; Baseline: 9.0 g/dL; Drop: 5.6 g/dL |
| Welsh and Bai 2015         | Patient 1: 57-year-old male Patient 2: 35-year-old female Patient 3: 56-year-old female | Patient 1: 100 g for 5 days Patient 2: Unspecified dosage for 8 days Patient 3: 180 g over 3 days | N.R.               | Patient 1: GBS Patient 2: ITP Patient 3: nonischemic cardiomyopathy | Patient 1: A+ Patient 2: O+ Patient 3: A+ | Patient 1: Nadir: 4.6 g/dL; Baseline: 14.4 g/dL; Drop: 9.8 g/L Patient 2: Nadir: 1.5 g/dL; Baseline: 14.6 g/dL; Drop: 13.1 g/L Patient 3: hemoglobin levels remained stable |
| Luban et al. 2015          | Patient 1: 16-year-old female Patient 2: 4-year-old female Patient 3: 7-year-old female Patient 4: 3-month-old female Patient 5: 10-month-old male | Patient 1: 3 doses over 8 days, with a cumulative dose of 3 g/kg Patient 2: 2 doses over 2 days, with a cumulative dose of 1.2 g/kg Patient 3: 2 doses 2 days apart, with a cumulative dose of 2 g/kg Patient 4: 2 doses over 24 hours with a cumulative dose of 4 g/kg Patient 5: 2 doses 2 days apart, with a cumulative dose of 4 g/kg | N.R.               | Patient 1: atypical KD Patient 2: KD Patient 3: atypical KD Patient 4: KD Patient 5: KD | Patient 1: AB D+ Patient 2: A D+ Patient 3: A D+ Patient 4: A+ Patient 5: AB D+ | Patient 1: Drop: 4 g/dL Patient 2: N.R. Patient 3: Drop: 2.3 g/dL Patient 4: Drop: 2.6 g/dL Patient 5: Drop: 5 g/dL |

(Continues)
PATIENT-ASSOCIATED RISK FACTORS FOR IVIG HEMOLYSIS

5.1 Observational real-world studies

When examining hemolysis cases, nine of the 16 real-world studies included blood group details of patients; with the majority of hemolysis cases observed in patients with blood group A (range 20%–100%), followed by blood group AB or B (ranges 17%–42% and 0%–29% respectively). This highlights the high incidence of hemolysis in non-blood group O patients, particularly in blood group AB, which has one of the highest incidence rates despite a low population prevalence. In regards to gender breakdown, in one study, IVIG-related hemolysis incidence was lower in female versus male patients (28% vs. 72%, respectively), and in four articles it was greater in female versus male patients (83% vs. 17%, 50% vs. 45%, 83% vs. 17%, and 58% vs. 42%, respectively). The reported incidence proportions of hemolysis ranged from 0% to 40% across all real-world studies (Table 1).

5.2 Clinical trials

The estimated incidence of hemolysis ranged from 0% to 21% in clinical trials (Table 1). Two studies reported the blood group details of the whole study population and blood group details of patients with hemolysis. A higher proportion of hemolysis cases were experienced in patients with blood group A or AB than in blood groups B or O. The study by Lakkaraja et al., 12.7% of hemolysis cases were observed in patients with blood group AB from a study population where only 4% of patients were blood group AB. In the study by Mielke et al., 83% of hemolysis cases were observed in patients with blood group A from a study population where 53% were blood group A. In both studies, the lowest rates of hemolysis cases were observed in patients with blood group O. In the Lakkaraja et al. study, 4.8% of hemolysis cases were observed in patients with blood group O from a study population of 45% blood group O patients. In the Mielke et al. study, no hemolysis cases were observed within the 28% of the study population having blood group O.
was observed in a cohort of pregnant women. No other clinical studies detailed gender breakdown.

5.3 | Case studies

A further 19 cases of hemolysis were identified in case reports and case series (Table 2). The number of hemolysis cases was slightly greater in females (nine cases out of 16 cases where sex was reported (56%), and patients were aged between 3 months to 75 years old). Of the 19 cases, seven were in pediatric patients (<18 years old), three patients were aged between 18 and 50 years old, and nine were in patients over 50 years of age. The most common indication was KD (seven cases followed by GBS (six cases; including one patient with Miller Fisher syndrome, a subtype of GBS), ITP (two cases) or MG (two cases). Other cases reported CIDP or non-ischemic cardiomyopathy. Of the 19 cases, 11 patients were blood group A, five were blood group AB, two were blood group O, and one was blood group B.

5.4 | Product-associated risk factors for IVIG hemolysis

IVIG-related hemolysis incidence was greatest in patients who received high doses (≥2 g/kg) of IVIG, with up to 89% and 11% of patients experiencing hemolysis with doses of ≥4 g/kg and 2 g/kg, respectively. In the study by Quinti et al., only six out of 162 patients (3.7%) receiving low doses of immunoglobulin (between 0.37 and 0.46 g/kg a month) had signs and symptoms of immunoglobulin-induced hemolysis. In one study which used the FAERS database, 83% of hemolysis cases were in patients who had ≥2 g/kg IVIG. This relationship was further observed across a number of additional studies using different IVIG products (Table 1).

Preparations of IVIG products were also shown to affect the incidence of hemolysis in some studies. In one study, incidence rates dropped from 1.49 to 0.1 per 100,000 when the manufacturing process of the IVIG product replaced the exclusion of high-anti-A-titer donors by specific immunoaffinity chromatography (IAC); reducing median anti-A and anti-B titers to 8 and 4, respectively. Incidence of hemolysis was also low in one study of patients treated with IVIG manufactured using an ethanol-octanoic acid (OA) process with additional cation and anion exchange chromatography, where only four IVIG-related hemolysis cases were recorded out of 562 patients. Furthermore, no hemolysis cases were observed in clinical trials that used IVIG products produced by Cohn fractionation or ethanol-OA fractionation followed by IAC isoagglutinin reduction. However, cases were observed in IVIG products that used ethanol-OA-purified products.

5.5 | Complications

Anemia severe enough to require transfusion of RBCs was a common complication that was reported in a number of studies. Case reports provided additional examples of complications, including dark urine and jaundice (one patient had chronic renal failure), hyperbilirubinemia in patients with KD, and acute kidney injury in a patient with ITP. However, it is worth noting that complications were not described in all studies, and as a result, the data may not provide a complete view of potential complications associated with IVIG-related hemolysis.

6 | DISCUSSION

In this review, we show the incidence of IVIG-related hemolysis as a percentage of all patients regardless of blood group, ranging from 0% to 19% in observational real-world studies and 0%–21% in clinical trials.

This large variance in IVIG-related hemolysis may be explained by variations in the definition of hemolysis (Table S1) and study design (including the timing of hemolysis assessment) and patient and product factors. For the definition of hemolysis, hemoglobin levels or drops in hemoglobin levels were used in conjunction with parameters such as (i) a positive direct antiglobulin test, (ii) elevated levels of lactate dehydrogenase or (iii) low haptoglobin; one study by Lakkaraja M et al. considered a hemoglobin level of less than 10 g/L anemia, presumably due to hemolysis. Moreover, some studies only included patients with hemolysis (assessing clinically significant or severe hemolytic anemia), whereas others made a distinction between clinically significant hemolysis (recorded adverse event) and laboratory signs of hemolysis (blood sampling), and some studies did not specify the definition used.

The assessment time point of hemolysis also differed across studies. In clinical trials, the cut-off period for hemolysis to be considered IVIG-treatment-related in clinical trials is commonly 10 days, with limited differences observed between utilizing a 10-day or 30-day risk period. Some studies in this review used a shorter cut-off period for example, 1 or 3 days, which may lead to cases being missed.

Patient factors such as blood group and comorbidities influence the differences in hemolysis proportions reported across studies. Blood groups A and AB are associated with the greatest risk of hemolysis risk.
followed by blood group B and blood group O. This observation is supported in this review, as in studies when blood group distribution was reported, greater hemolysis risk was observed in patients with blood group A and AB. This is effectively demonstrated in the prospective observational study by Pendergrast et al., which assessed the incidence of IVIG-mediated hemolysis in non-blood group O patients that were administered a high dose of IVIG (2 g/kg). This study concluded that patients with blood group AB were at a significantly increased risk of hemolysis compared to patients with blood group A or B (89% vs. 33% vs. 36%, respectively). Furthermore, the study by Bruggeman et al. reported that IVIG-related hemolysis was greatest in patients with blood group AB, with no IVIG-related hemolysis cases observed in patients with blood group O. In addition, Pendergrast et al. showed that hemolysis risk is associated with ABO zygosity, but not secretor status or Fc receptor polymorphisms suggesting patients with heterozygous A or B may be protected. Differences in patient co-morbidities and underlying health conditions may also affect hemolysis risk. A high incidence of hemolysis has been observed among studies and case reports in patients with KD: a rare disease where hemolysis risk appears much greater than in most other conditions for which IVIG is indicated. This increased risk could be related to patients’ underlying inflammatory state. In addition, high-dose immunomodulatory therapy (typically 2 g/kg) is standard in this indication and is sometimes increased to a cumulative dose of 4 g/kg. Additionally, the IVIG product itself can influence the incidence of hemolysis, with higher IVIG doses associated with a higher risk of hemolysis. Data from the FAERS database showed that the majority of patients (n = 66/80) who experienced IVIG-related hemolysis were treated with IVIG doses of ≥2 g/kg IVIG. The production of IVIG can also impact the incidence of hemolysis. In studies where the specific IVIG product was named, different hemolysis incidence proportions were observed and were associated with isoagglutinins levels in the final manufactured product. Previous studies have shown that the anti-A and anti-B content of IVIGs correlate with the risk of Ig-related hemolysis. Anti-A donor screening and exclusion has been attempted but were found to produce only a moderate reduction in isoagglutinins, following exclusion of about 5% of donors with high anti-A. Alterations to the manufacturing process have also been attempted to further reduce isoagglutinins in the final IVIG product. Most modern, large-scale Ig manufacturing processes are based on combinations of cold ethanol precipitation, to separate IgG from albumin, followed by precipitation and chromatographic steps to increase IgG purity. In the Cohn fractionation process, isoagglutinins are reduced with the elimination of FrIII, which beyond IgM contains most IgG.
isoagglutinins. Other processes that have replaced the elimination of FrIII still remove IgM and with it most isoagglutinins; however, they may or may not reduce IgG isoagglutinin, for example, polyethylene glycol (PEG) precipitation reduces isoagglutinins whereas OA precipitation does not. Modern IVIG purification processes include anion exchange chromatography steps that increase the purity of IgG but do not reduce levels of isoagglutinins. Some IVIG purification processes include a specific immunoaffinity isoagglutinin reduction step, with a recent study showing that hemolytic events are significantly reduced from around 4.05 cases at baseline (per 1000 kg) to 0.50 cases when immunoaffinity chromatography (IAC) is utilized. An overview of the main production processes and resulting isoagglutinin content is shown in Figure 2.

In studies that reported IVIG dose and product, the majority of hemolytic events occur with IVIG products produced by ethanol-OA fractionation given at a high dose (>2 g/kg), with incidence rates of 0.7%–21.1% observed. Only a few hemolytic events have been reported when products produced by Cohn fractionation, ethanol-PEG, and ethanol-OA plus IAC were given. This suggests an association between an increased risk of hemolysis with increased amounts of isoagglutinins administered to the patient. However, further analyses to investigate this relationship and the impact of patient risk factors, like blood group, are required.

Limitations of this study include: first, studies had diverse patient inclusion criteria and definitions of hemolysis; second, many of the studies were not of high quality, with most being retrospective, some prospective observational, and none randomized controlled; and finally, this review only selected studies available on Embase written in English.

## 7 CONCLUSION

In conclusion, the incidence of IVIG-related hemolysis differed across study types, ranging from 0% to 19% in observational studies and from 0% to 21% in clinical trials. Several factors appear to influence the risk of IVIG-related hemolysis, including blood groups AB, A, and B, high dose IVIG therapy, and products with anti-A/B. Therefore, monitoring patients for hemolysis is warranted particularly in these patient groups. IVIG production technique and the resulting isoagglutinin content may play a major role as well.

## ACKNOWLEDGMENTS

The authors wish to thank Ami Patel for her valuable contribution to this manuscript. Editorial assistance was provided by Meridian HealthComms Ltd, funded by CSL Behring.

**CONFLICT OF INTEREST**

Hillary Cuesta was a CSL employee at the time of development; Ibrahim El Menyawi, Alphonse Hubsch, Liane Hoefferer, Orell Mielke, Susie Gabriel, and Amgad Shebl are employees of CSL Behring.

**ORCID**

Alphonse Hubsch 🐣 https://orcid.org/0000-0001-7139-0526

Amgad Shebl 🐣 https://orcid.org/0000-0001-5376-4168

**REFERENCES**

1. Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139: S1–S46.

2. Bellac CL, Hottiger T, Jutzi MP, Bögli-Stuber K, Sänger M, Hanschmann KM, et al. The role of isoagglutinins in intravenous immunoglobulin-related hemolysis. Transfusion. 2015;55(suppl 2):S13–22.

3. Branch DR. Anti-a and anti-B: what are they and where do they come from? Transfusion. 2015;55(suppl 2):74–9.

4. Panch SR, Montemayor-Garcia C, Klein HG. Hemolytic transfusion reactions. N Engl J Med. 2019;381:150–62.

5. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

6. Keh R, Kahlil A, Nihoyannopoulos L, Compton L, Kapoor M, Gosal D, et al. Routine blood monitoring in maintenance immunoglobulin treatment of inflammatory neuropathy: is it clinically relevant? J Neurol Sci. 2020;408:116527.

7. Nolan BE, Wang Y, Pary P, Luban NLC, Wong ECC, Ronis T. High-dose intravenous immunoglobulin is strongly associated with hemolytic anemia in patients with Kawasaki disease. Transfusion. 2018;58:2564–71.

8. Cicha A, Fischer MB, Wringer A, Haas S, Bauer WM, Wolf HM, et al. Effect of intravenous immunoglobulin administration on erythrocyte and leucocyte parameters. J Eur Acad Dermatol Venereol. 2018;32:1004–10.

9. Sridhar G, Ekezuwe BF, Izurieta HS, Forshee RA, Selvam N, Mintz PD, et al. Occurrence of hemolytic reactions on the same day as immune globulin product administrations during 2008 to 2014. Transfusion. 2018;58:70–80.

10. Liu X, Treister R, Lang M, Oaklander AL. IVlg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety. Ther Adv Neurol Disord. 2018;11:1756285617744484.

11. Donga PZ, Bilir SP, Little G, Babinchak T, Munakata J. Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura. J Med Econ. 2017;20:1200–6.

12. Akman AO, Kara FK, Koksal S, Cakir BC, Karagol C, Sayli T. Association of hemolysis with high dose intravenous immunoglobulin therapy in pediatric patients: an open-label prospective trial. Transfus Apher Sci. 2017;56:531–4.

13. Levine AA, Levine TD, Clarke K, Saperstein D. Renal and hematologic side effects of long-term intravenous...
immunoglobulin therapy in patients with neurologic disorders. Muscle Nerve. 2017;56:1173–6.
14. Winiecki S, Baer B, Chege W, Jankosky C, Mintz P, Baker M, et al. Complementary use of passive surveillance and mini-sentinel to better characterize hemolysis after immune globulin. Transfusion. 2015;55(suppl 2):S28–35.
15. Quinti I, Pulvirenti F, Milito C, Granata G, Giovannetti G, la Marra F, et al. Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment. Transfusion. 2015;55:1067–74.
16. Ghiasi M, Daneshpazhooh M, Balighi K, et al. Adverse reactions associated with intravenous immunoglobulin therapy in patients with dermatologic diseases: an 11-year retrospective study. Iran J Dermatol. 2017;20:6–10.
17. Wallenhorst C, Patel A, Shebl A, Hubsch A, Simon TL, Martinez C. Anti-a/b isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort study. Transfusion. 2020;60:1381–90.
18. Van Anh KY, Shah S, Tremoulet AH. Hemolysis from intravenous immunoglobulin in obese patients with Kawasaki disease. Front Pediatr. 2020;8:146.
19. Bruggeman CW, Nagelkerke SQ, Lau W, Manlhiot C, de Haas M, van Bruggen R, et al. Treatment-associated hemolysis in Kawasaki disease: association with blood-group antibody titers in IVIG products. Blood Adv. 2020;4:3416–26.
20. Tong TN, Blacquiere M, Sakac D, Burke-Murphy E, Yi Q, Callum J, et al. The utility of a monocyte monolayer assay in the assessment of intravenous immunoglobulin-associated hemolysis. Transfusion. 2020;60:3010–8.
21. Pendergrast J, Armaili C, Callum J, Cserti-Gazdewich C, Jiwajej A, Lieberman L, et al. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis. Transfusion. 2021;61:1053–63.
22. Leger JM, Alfa Cisse O, Cocito D, et al. IgYmune® is an effective maintenance treatment for multifocal motor neuropathy: a randomized, double-blind, multi-center cross-over non-inferiority study versus Kiovig®-the LIME study. J Peripher Nerv Syst. 2019;24:56–63.
23. Koochakzadeh L, Fekri K, Pakzad R, Khabazkhoob M. Comparison of the therapeutic effect of anti-D IG and IVIG in children with acute immune thrombocytopenic purpura attending a Children’s medical center: a randomized, double-blind, controlled clinical trial. Journal of comprehensive. Pediatrics. 2018;9:e12334.
24. Mielke O, Fontana S, Goranova-Marinova V, Shebl A, Sypcher MO, Wymann S, et al. Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group a and B antibodies and individual susceptibility. Transfusion. 2017;57:2629–38.
25. Viallard J-F, Brion J-P, Malphettes M, Durieu I, Gardembas M, Schleinitz N, et al. A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID). Rev Med Interne. 2017;38:578–84.
26. Lakkaraja M, Jin JC, Manotas KC, Vinograd CA, Ferd P, Gabor J, et al. Blood group a mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia. Transfusion. 2016;56:2449–54.
27. Melamed I, Gupta S, Stratford Bobbitt M, et al. Efficacy and safety of Gammaplex® 5% in children and adolescents with primary immunodeficiency diseases. Clin Exp Immunol. 2016;184:228–36.
28. Karelis G, Balasa R, De Bleecker JL, et al. A phase 3 multicenter, prospective, open-label efficacy and safety study of immune globulin (human) 10% Caprylate/chromatography purified in patients with myasthenia gravis exacerbations. Eur Neurol. 2019;81:223–30.
29. Nobile-Orazio E, Pujol S, Kasiborski F, Ouaja R, Corte GD, Bonet R, et al. An international multicenter efficacy and safety study of IgYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study. J Peripher Nerv Syst. 2020;25:356–65.
30. Shimomura M, Okura Y, Ohta O, Takahashi Y, Kobayashi I. Autoimmune haemolytic anaemia caused by anti-M antibody in a patient with Kawasaki disease. Mod Rheumatol Case Rep. 2020;4:99–101.
31. Chahda J, Levine RL, Ilyas O. IVIG-induced abrupt hemolysis in neurological conditions. Blood. 2019;134:4991.
32. Lasica M, Zantromi D. Severe intravenous immunoglobulin-induced hemolysis with pigment nephropathy managed with red cell exchange. J Clin Apher. 2016;31:464–6.
33. Sharma A, Aryal D. Hemolysis induced cross-matching difficulty with intravenous immunoglobulin: a case report. J Med Case Rep. 2018;12:245.
34. Welsh KJ, Bai Y. Therapeutic plasma exchange as a therapeutic modality for the treatment of IVIG complications. J Clin Apher. 2015;30:371–4.
35. Luban NL, Wong EC, Henrich Lobo R, et al. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease. Transfusion. 2015;55(suppl 2):S90–4.
36. Jacobs J, Kneib J, Gabbard A. Intravenous immunoglobulin-associated hemolytic anemia. Lab Med. 2020;51:e47–50.
37. Nguyen TP, Biliciler S, Wahed A, Sheikh K. Occurrence of hemolytic anemia in patients with GBS treated with high-dose IV Ig. Neurrol Neuroimmunol Neuroinflamm. 2014;1:e50.
38. Flegel WA. Pathogenesis and mechanisms of antibody-mediated hemolysis. Transfusion. 2015;55(suppl 2):S47–58.
39. Tocan V, Inaba A, Kurano T, Sonoda M, Soebijanto K, Nakayama H. Severe hemolytic anemia following intravenous immunoglobulin in an infant with Kawasaki disease. J Pediatr Hematol Oncol. 2017;39:e100–e2.
40. Berg R, Shebl A, Kimber MC, Abraham M, Schreiber GB. Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012. Transfusion. 2015;55(suppl 2):S36–46.
41. Taylor E, Vu D, Legare C, Keene D. Intravenous immune globulin-related hemolysis: comparing two different methods for case assessment. Transfusion. 2015;55(suppl 2):S23–7.
42. van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17:35–46.
43. Padmore R. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports. Transfusion. 2015;55(Suppl 2):S59–64.

44. Siani B, Willimann K, Wymann S, Marques Antunes A, Widmer E. Donor screening reduces the isoagglutinin titer in immunoglobulin products. Transfusion. 2015;55(Suppl 2):S95–S7.

45. Cohn EJ, Strong LE, Hughes WL, Mulford DJ, Ashworth JN, Melin M, et al. Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 1946;68:459–75.

46. Shebl A, Gabriel S, Van Dinther K, et al. Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports. Transfusion. 2020;60:1278–86.

47. Romberg V, Hoefferer L, El Menyawi I. Effects of the manufacturing process on the anti-a isoagglutinin titers in intravenous immunoglobulin products. Transfusion. 2015;55(suppl 2):S105–9.

48. Gerber S, Gaida A, Spiegl N, Wymann S, Antunes AM, Menyawi IE, et al. Reduction of Isoagglutinin in intravenous immunoglobulin (IVIG) using blood group A- and B-specific Immunoaffinity chromatography: industry-scale assessment. BioDrugs. 2016;30:441–51.

49. Hoefferer L, Glauser I, Gaida A, Willimann K, Marques Antunes A, Siani B, et al. Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products. Transfusion. 2015;55(suppl 2):S117–21.

50. Walker JM. The protein protocols handbook. 3rd ed. New York, N.Y: Humana Press; 2009.

51. Dhainaut F, Guillaumat PO, Dib H, Perret G, Sauger A, de Coupade C, et al. In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations. Vox Sang. 2013;104:115–26.

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.